Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Increasing pazopanib exposure by splitting intake moments

Trial Profile

Increasing pazopanib exposure by splitting intake moments

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma; Soft tissue sarcoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top